Search

Your search keyword '"Tobimatsu, Kazutoshi"' showing total 42 results
Start Over Author "Tobimatsu, Kazutoshi"
42 results on '"Tobimatsu, Kazutoshi"'

1. Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113

Author

Okuno, Tatsuya, Morizane, Chigusa, Mizusawa, Junki, Yanagimoto, Hiroaki, Kobayashi, Satoshi, Imaoka, Hiroshi, Terashima, Takeshi, Kawakami, Hisato, Sano, Yusuke, Okusaka, Takuji, Ikeda, Masafumi, Ozaka, Masato, Miwa, Haruo, Todaka, Akiko, Shimizu, Satoshi, Mizuno, Nobumasa, Sekimoto, Mitsugu, Sano, Keiji, Tobimatsu, Kazutoshi, Katanuma, Akio, Gotoh, Kunihito, Yamaguchi, Hironori, Ishii, Hiroshi, Furuse, Junji, and Ueno, Makoto

Published
2024
Full Text
View/download PDF

3. The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113

Author

Yamada, Ikuhiro, Morizane, Chigusa, Okusaka, Takuji, Mizusawa, Junki, Kataoka, Tomoko, Ueno, Makoto, Ikeda, Masafumi, Okano, Naohiro, Todaka, Akiko, Shimizu, Satoshi, Mizuno, Nobumasa, Sekimoto, Mitsugu, Tobimatsu, Kazutoshi, Yamaguchi, Hironori, Nishina, Tomohiro, Shirakawa, Hirofumi, Kojima, Yasushi, Oono, Takamasa, Kawamoto, Yasuyuki, Furukawa, Masayuki, Iwai, Tomohisa, Sudo, Kentaro, Okamura, Keiya, Yamashita, Tatsuya, Kato, Naoya, Shioji, Kazuhiko, Shimizu, Kyouko, Nakagohri, Toshio, Kamata, Ken, Ishii, Hiroshi, and Furuse, Junji

Published
2022
Full Text
View/download PDF

6. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

Author

Okano, Naohiro, Morizane, Chigusa, Nomura, Shogo, Takahashi, Hideaki, Tsumura, Hidetaka, Satake, Hironaga, Mizuno, Nobumasa, Tsuji, Kunihiro, Shioji, Kazuhiko, Asagi, Akinori, Yasui, Kohichiroh, Kitagawa, Sho, Kashiwada, Tomomi, Ishiguro, Atsushi, Kanai, Masashi, Ueno, Makoto, Ogura, Takashi, Shimizu, Satoshi, Tobimatsu, Kazutoshi, Motoya, Masayo, Nakashima, Koji, Ikeda, Masafumi, Okusaka, Takuji, and Furuse, Junji

Published
2020
Full Text
View/download PDF

7. Early Tumor Shrinkage and Depth of Response as Predictors of Survival for Advanced Biliary Tract Cancer: An Exploratory Analysis of JCOG1113.

Author

Okano, Naohiro, Morizane, Chigusa, Okusaka, Takuji, Sadachi, Ryo, Kataoka, Tomoko, Kobayashi, Satoshi, Ikeda, Masafumi, Ozaka, Masato, Mizutani, Tomonori, Sugimori, Kazuya, Todaka, Akiko, Shimizu, Satoshi, Mizuno, Nobumasa, Yamamoto, Tomohisa, Sano, Keiji, Tobimatsu, Kazutoshi, Katanuma, Akio, Gotoh, Kunihito, Yamaguchi, Hironori, and Ishii, Hiroshi

Subjects
DISEASE progression, BILE duct tumors, CONFIDENCE intervals, CANCER chemotherapy, MULTIVARIATE analysis, TREATMENT effectiveness, GEMCITABINE, RESEARCH funding, CISPLATIN, PROGRESSION-free survival, TUMOR markers, PROPORTIONAL hazards models, OVERALL survival, EVALUATION
Abstract

Background Recent studies suggest that early tumor shrinkage (ETS) and depth of response (DpR) reflect outcomes of chemotherapy in various cancers. This study evaluated the association of ETS and DpR with clinical outcomes using data from JCOG1113, which demonstrated the non-inferiority of gemcitabine plus S-1 (GS) to gemcitabine plus cisplatin (GC) for chemotherapy-naïve advanced biliary tract cancer. Material and Methods In total, 354 (289 with measurable target lesions) patients enrolled in JCOG1113 were divided into ETS-unachieved and ETS-achieved groups (≥20% tumor reduction at week 6) and DpR-low and DpR-high groups (≥40% maximum shrinkage) until 12 weeks after enrollment. The impact of ETS and DpR on survival outcome was evaluated using the multivariable Cox proportional hazard model. Results The proportions of patients in the ETS-achieved and DpR-high groups were similar between the 2 treatment arms. The hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS) for the ETS-achieved group were 0.70 (95% confidence interval (CI), 0.52-0.93) and 0.60 (95%CI, 0.44-0.81), respectively. The HRs of PFS and OS for the DpR-high group were 0.67 (95%CI, 0.48-0.94) and 0.64 (95%CI, 0.46-0.90), respectively. In the subpopulation treatment effect pattern plot analysis, most patients in the ETS-achieved group in the GC arm did not experience disease progression after 12 weeks from the landmark. Conclusion As on-treatment markers, ETS and DpR were effective tools. ETS was clinically useful, because it can be used to evaluate the outcomes of treatment early at a specific time. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Comparison of clinical features by primary sites in patients with biliary tract cancer who received gemcitabine-based chemotherapy: An exploratory analysis of JCOG1113.

Author

Suzuki, Yuko, primary, Morizane, Chigusa, additional, Mizusawa, Junki, additional, Sano, Yusuke, additional, Kobayashi, Satoshi, additional, Imaoka, Hiroshi, additional, Terashima, Takeshi, additional, Ikeda, Masafumi, additional, Okano, Naohiro, additional, Sugimori, Kazuya, additional, Todaka, Akiko, additional, Shimizu, Satoshi, additional, Mizuno, Nobumasa, additional, Sekimoto, Mitsugu, additional, Sano, Keiji, additional, Tobimatsu, Kazutoshi, additional, Katanuma, Akio, additional, Okusaka, Takuji, additional, Ozaka, Masato, additional, and Ueno, Makoto, additional

Published
2023
Full Text
View/download PDF

9. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgroup analysis on systemic inflammatory response in JCOG1106.

Author

Mizuno, Nobumasa, Ioka, Tatsuya, Ogawa, Gakuto, Nakamura, Satoaki, Hiraoka, Nobuyoshi, Ito, Yoshinori, Katayama, Hiroshi, Takada, Ryoji, Kobayashi, Satoshi, Ikeda, Masafumi, Miwa, Haruo, Okano, Naohiro, Kuramochi, Hidekazu, Sekimoto, Mitsugu, Okusaka, Takuji, Ozaka, Masato, Todaka, Akiko, Gotoh, Kunihito, Tobimatsu, Kazutoshi, and Yamaguchi, Hironori

Published
2023
Full Text
View/download PDF

10. The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113.

Author

Okuno, Tatsuya, primary, Morizane, Chigusa, additional, Okusaka, Takuji, additional, Mizusawa, Junki, additional, Kataoka, Tomoko, additional, Ikeda, Masafumi, additional, Ozaka, Masato, additional, Sugimori, Kazuya, additional, Todaka, Akiko, additional, Shimizu, Satoshi, additional, Mizuno, Nobumasa, additional, Sekimoto, Mitsugu, additional, Sano, Keiji, additional, Tobimatsu, Kazutoshi, additional, Katanuma, Akio, additional, Gotoh, Kunihito, additional, Yamaguchi, Hironori, additional, Ishii, Hiroshi, additional, Ueno, Makoto, additional, and Furuse, Junji, additional

Published
2022
Full Text
View/download PDF

13. Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601

Author

Iwatsuki, Masaaki, primary, Orita, Hiroyuki, additional, Kobayashi, Kazuma, additional, Hidaka, Shigekazu, additional, Arigami, Takaaki, additional, Kusumoto, Tetsuya, additional, Satake, Hironaga, additional, Oki, Eiji, additional, Tsutsumi, Satoshi, additional, Tobimatsu, Kazutoshi, additional, Shimokawa, Mototsugu, additional, Saeki, Hiroshi, additional, Makiyama, Akitaka, additional, Baba, Hideo, additional, and Mori, Masaki, additional

Published
2021
Full Text
View/download PDF

15. Dok1 mediates high-fat diet--induced adipocyte hypertrophy and obesity through modulation of PPAR-[gamma] phosphorylation

Author

Hosooka, Tetsuya, Noguchi, Tetsuya, Kotani, Ko, Nakamura, Takehiro, Sakaue, Hiroshi, Inoue, Hiroshi, Ogawa, Wataru, Tobimatsu, Kazutoshi, Takazawa, Kazuo, Sakai, Mashito, Matsuki, Yasushi, Hiramatsu, Ryuji, Yasuda, Tomoharu, Lazar, Mitchell A., Yamanashi, Yuji, and Kasuga, Masato

Subjects
Ketogenic diet -- Health aspects, Ketogenic diet -- Research, Hypertrophy -- Risk factors, Hypertrophy -- Genetic aspects, Hypertrophy -- Research, Obesity -- Risk factors, Obesity -- Genetic aspects, Obesity -- Research, Phosphorylation -- Research, Protein tyrosine kinase -- Physiological aspects, Protein tyrosine kinase -- Genetic aspects, Protein tyrosine kinase -- Research
Abstract

Insulin receptor substrate (IRS)-1 and IRS-2 have dominant roles in the action of insulin (1), but other substrates of the insulin receptor kinase, such as Gabl, c-Cbl, SH2-B and APS, are also of physiological relevance (2-5). Although the protein downstream of tyrosine kinases-1 (Dok1) is known to function as a multisite adapter molecule in insulin signaling (6-8), its role in energy homeostasis has remained unclear. Here we show that Dok1 regulates adiposity. Expression of Dok1 in white adipose tissue was markedly increased in mice fed a high-fat diet, whereas adipocytes lacking this adapter were smaller and showed a reduced hypertrophic response to this dietary manipulation. Dok1-deficient mice were leaner and showed improved glucose tolerance and insulin sensitivity compared with wild-type mice. Embryonic fibroblasts from Dok1-deficient mice were impaired in adipogenic differentiation, and this defect was accompanied by an increased activity of the protein kinase ERK and a consequent increase in the phosphorylation of peroxisome proliferator-activated receptor (PPAR)-[gamma] on Ser112. Mutation of this negative regulatory site for the transactivation activity of PPAR-[gamma] blocked development of the lean phenotype caused by Dok1 ablation. These results indicate that Dok1 promotes adipocyte hypertrophy by counteracting the inhibitory effect of ERK on PPAR-[gamma] and may thus confer predisposition to diet-induced obesity., We and others have shown that tyrosine-phosphorylated Dok1 binds and recruits p120 Ras GTPase-activating protein (rasGAP) as well as the adapter protein Nck, thereby regulating mitogenic signaling mediated by Ras [...]

Published
2008

17. Analysis of early tumor shrinkage and depth of response in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin or gemcitabine plus S-1: An exploratory analysis of JCOG1113.

Author

Okano, Naohiro, primary, Morizane, Chigusa, additional, Okusaka, Takuji, additional, Sadachi, Ryo, additional, Kataoka, Tomoko, additional, Ueno, Makoto, additional, Ikeda, Masafumi, additional, Ozaka, Masato, additional, Sugimori, Kazuya, additional, Todaka, Akiko, additional, Shimizu, Satoshi, additional, Mizuno, Nobumasa, additional, Yamamoto, Tomohisa, additional, Sano, Keiji, additional, Tobimatsu, Kazutoshi, additional, Katanuma, Akio, additional, Miyamoto, Atsushi, additional, Yamaguchi, Hironori, additional, Ishii, Hiroshi, additional, and Furuse, Junji, additional

Published
2021
Full Text
View/download PDF

18. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)

Author

Sai, Satoshi, primary, Toyoda, Masanori, additional, Tobimatsu, Kazutoshi, additional, Satake, Hironaga, additional, Yasui, Hisateru, additional, Kimbara, Shiro, additional, Koyama, Taiji, additional, Fujishima, Yoshimi, additional, Imamura, Yoshinori, additional, Funakoshi, Yohei, additional, Kiyota, Naomi, additional, Toyama, Hirochika, additional, Kodama, Yuzo, additional, and Minami, Hironobu, additional

Published
2020
Full Text
View/download PDF

19. Muscle-Specific Overexpression of Heparin-Binding Epidermal Growth Factor-Like Growth Factor Increases Peripheral Glucose Disposal and Insulin Sensitivity

Author

Fukatsu, Yasuhide, Noguchi, Tetsuya, Hosooka, Tetsuya, Ogura, Takeshi, Kotani, Ko, Abe, Takaya, Shibakusa, Tetsuro, Inoue, Kazuo, Sakai, Mashito, Tobimatsu, Kazutoshi, Inagaki, Kenjiro, Yoshioka, Toyo, Matsuo, Masahiro, Nakae, Jun, Matsuki, Yasushi, Hiramatsu, Ryuji, Kaku, Kohei, Okamura, Hitoshi, Fushiki, Tohru, and Kasuga, Masato

Published
2009

20. Update on phase II trial of cetuximab plus S-1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06

Author

Sunakawa, Yu, primary, Ichikawa, Wataru, additional, Hagiwara, Ken, additional, Tsuda, Masahiro, additional, Takagane, Akinori, additional, Yasui, Hisateru, additional, Satake, Hironaga, additional, Denda, Tadamichi, additional, Segawa, Yoshihiko, additional, Tanioka, Hiroaki, additional, Kotaka, Masahito, additional, Kochi, Mitsugu, additional, Watanabe, Takanori, additional, Nakamura, Masato, additional, Tsuji, Akihito, additional, Tani, Satoshi, additional, Negoro, Yuji, additional, Tobimatsu, Kazutoshi, additional, Takeuchi, Masahiro, additional, and Fujii, Masashi, additional

Published
2019
Full Text
View/download PDF

21. Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer

Author

Tsumura, Hidetaka, primary, Morizane, Chigusa, additional, Nomura, Shogo, additional, Takahashi, Hideaki, additional, Okano, Naohiro, additional, Mizuno, Nobumasa, additional, Satake, Hironaga, additional, Tsuji, Kunihiro, additional, Shioji, Kazuhiko, additional, Asagi, Akinori, additional, Yasui, Kohichiroh, additional, Miyakawa, Hiroyuki, additional, Ishiguro, Atsushi, additional, Ogura, Takashi, additional, Ueno, Makoto, additional, Tobimatsu, Kazutoshi, additional, Terashima, Takeshi, additional, Ikeda, Masafumi, additional, Okusaka, Takuji, additional, and Furuse, Junji, additional

Published
2019
Full Text
View/download PDF

22. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE)

Author

Chayahara, Naoko, primary, Mukohara, Toru, additional, Tachihara, Motoko, additional, Fujishima, Yoshimi, additional, Fukunaga, Atsushi, additional, Washio, Ken, additional, Yamamoto, Masatsugu, additional, Nakata, Kyosuke, additional, Kobayashi, Kazuyuki, additional, Takenaka, Kei, additional, Toyoda, Masanori, additional, Kiyota, Naomi, additional, Tobimatsu, Kazutoshi, additional, Doi, Hisayo, additional, Mizuta, Naomi, additional, Marugami, Naho, additional, Kawaguchi, Atsushi, additional, Nishigori, Chikako, additional, Nishimura, Yoshihiro, additional, and Minami, Hironobu, additional

Published
2019
Full Text
View/download PDF

23. The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113.

Author

Ueno, Makoto, primary, Morizane, Chigusa, additional, Okusaka, Takuji, additional, Ogawa, Gakuto, additional, Sato, Yuya, additional, Ikeda, Masafumi, additional, Ozaka, Masato, additional, Sugimori, Kazuya, additional, Fukutomi, Akira, additional, Hara, Hiroki, additional, Mizuno, Nobumasa, additional, Yanagimoto, Hiroaki, additional, Sano, Keiji, additional, Tobimatsu, Kazutoshi, additional, Yane, Kei, additional, Nakamori, Shoji, additional, Sata, Naohiro, additional, Nishina, Tomohiro, additional, Ishii, Hiroshi, additional, and Furuse, Junji, additional

Published
2019
Full Text
View/download PDF

24. The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113.

Author

Yamada, Ikuhiro, primary, Morizane, Chigusa, additional, Okusaka, Takuji, additional, Ogawa, Gakuto, additional, Sato, Yuya, additional, Ueno, Makoto, additional, Ikeda, Masafumi, additional, Sugimori, Kazuya, additional, Fukutomi, Akira, additional, Shimizu, Satoshi, additional, Mizuno, Nobumasa, additional, Yanagimoto, Hiroaki, additional, Sano, Keiji, additional, Tobimatsu, Kazutoshi, additional, Yane, Kei, additional, Nakamori, Shoji, additional, Sata, Naohiro, additional, Nishina, Tomohiro, additional, Ishii, Hiroshi, additional, and Furuse, Junji, additional

Published
2019
Full Text
View/download PDF

25. Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.

Author

Ueno, Makoto, Morizane, Chigusa, Okusaka, Takuji, Mizusawa, Junki, Kataoka, Tomoko, Ikeda, Masafumi, Ozaka, Masato, Okano, Naohiro, Sugimori, Kazuya, Todaka, Akiko, Shimizu, Satoshi, Mizuno, Nobumasa, Yamamoto, Tomohisa, Sano, Keiji, Tobimatsu, Kazutoshi, Katanuma, Akio, Miyamoto, Atsushi, Yamaguchi, Hironori, Nishina, Tomohiro, and Shirakawa, Hirofumi

Subjects
CANCER chemotherapy, BILIARY tract cancer, CREATININE, HEMATOLOGY, CISPLATIN, GEMCITABINE
Abstract

JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). However, poor renal function often results in high toxicity of S-1. Therefore, we examined whether GS can be recommended for patients with low creatinine clearance (CCr). Renal function was classified by CCr as calculated by the Cockcroft-Gault formula: high CCr (CCr ≥ 80 ml/min) and low CCr (80 > CCr ≥ 50 ml/min). Of 354 patients, 87 patients on GC and 91 on GS were included in the low CCr group, while there were 88 patients on GC and 88 patients on GS in the high CCr group. The HR of overall survival for GS compared with GC was 0.687 (95% CI 0.504–0.937) in the low CCr group. Although the total number of incidences of all Grade 3–4 non-haematological adverse reactions was higher (36.0% vs. 11.8%, p = 0.0002), the number of patients who discontinued treatment was not different (14.1% vs. 16.9%, p = 0.679) for GS compared with GC in the low CCr group. This study suggests that GS should be selected for the treatment of advanced BTC patients with reduced renal function. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

26. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106.

Author

Ioka, Tatsuya, Furuse, Junji, Fukutomi, Akira, Mizusawa, Junki, Nakamura, Satoaki, Hiraoka, Nobuyoshi, Ito, Yoshinori, Katayama, Hiroshi, Ueno, Makoto, Ikeda, Masafumi, Sugimori, Kazuya, Okano, Naohiro, Shimizu, Kyoko, Yanagimoto, Hiroaki, Okusaka, Takuji, Ozaka, Masato, Todaka, Akiko, Nakamori, Shoji, Tobimatsu, Kazutoshi, and Sata, Naohiro

Published
2021
Full Text
View/download PDF

27. Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: a randomized comparative evaluation

Author

Fujishima, Yoshimi, primary, Chayahara, Naoko, additional, Tachihara, Motoko, additional, Fukunaga, Atsushi, additional, Washio, Ken, additional, Yamamoto, Masatsugu, additional, Toyoda, Masanori, additional, Tobimatsu, Kazutoshi, additional, Doi, Hisayo, additional, Mizuta, Naomi, additional, Kawaguchi, Atsushi, additional, Nishigori, Chikako, additional, Nishimura, Yoshihiro, additional, Mukohara, Toru, additional, and Minami, Hironobu, additional

Published
2018
Full Text
View/download PDF

28. Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT).

Author

Ueno, Makoto, primary, Morizane, Chigusa, additional, Okusaka, Takuji, additional, Mizusawa, Junki, additional, Katayama, Hiroshi, additional, Ikeda, Masafumi, additional, Ozaka, Masato, additional, Sugimori, Kazuya, additional, Fukutomi, Akira, additional, Hara, Hiroki, additional, Mizuno, Nobumasa, additional, Yanagimoto, Hiroaki, additional, Sano, Keiji, additional, Tobimatsu, Kazutoshi, additional, Yane, Kei, additional, Nakamori, Shoji, additional, Sata, Naohiro, additional, Yukisawa, Seigo, additional, Ishii, Hiroshi, additional, and Furuse, Junji, additional

Published
2018
Full Text
View/download PDF

29. Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: A randomized left-right comparative evaluation (APPEARANCE).

Author

Tachihara, Motoko, primary, Chayahara, Naoko, additional, Fujishima, Yoshimi, additional, Fukunaga, Atsushi, additional, Washio, Ken, additional, Yamamoto, Masatsugu, additional, Nakata, Kyosuke, additional, Kobayashi, Kazuyuki, additional, Takenaka, Kei, additional, Toyoda, Masanori, additional, Kiyota, Naomi, additional, Tobimatsu, Kazutoshi, additional, Doi, Hisayo, additional, Mizuta, Naomi, additional, Marugami, Naho, additional, Kawaguchi, Atsushi, additional, Nishigori, Chikako, additional, Nishimura, Yoshihiro, additional, Mukohara, Toru, additional, and Minami, Hironobu, additional

Published
2018
Full Text
View/download PDF

30. O2-2-3 [Encore] - Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer

Author

Tsumura, Hidetaka, Morizane, Chigusa, Nomura, Shogo, Takahashi, Hideaki, Okano, Naohiro, Mizuno, Nobumasa, Satake, Hironaga, Tsuji, Kunihiro, Shioji, Kazuhiko, Asagi, Akinori, Yasui, Kohichiroh, Miyakawa, Hiroyuki, Ishiguro, Atsushi, Ogura, Takashi, Ueno, Makoto, Tobimatsu, Kazutoshi, Terashima, Takeshi, Ikeda, Masafumi, Okusaka, Takuji, and Furuse, Junji

Published
2019
Full Text
View/download PDF

31. MO1-16-2 - Update on phase II trial of cetuximab plus S-1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06

Author

Sunakawa, Yu, Ichikawa, Wataru, Hagiwara, Ken, Tsuda, Masahiro, Takagane, Akinori, Yasui, Hisateru, Satake, Hironaga, Denda, Tadamichi, Segawa, Yoshihiko, Tanioka, Hiroaki, Kotaka, Masahito, Kochi, Mitsugu, Watanabe, Takanori, Nakamura, Masato, Tsuji, Akihito, Tani, Satoshi, Negoro, Yuji, Tobimatsu, Kazutoshi, Takeuchi, Masahiro, and Fujii, Masashi

Published
2019
Full Text
View/download PDF

34. Su1488 Long-Term Outcomes of Endoscopic Submucosal Dissection for M3 or SM Superficial Esophageal Squamous Cell Carcinoma Without Surgical Treatment

Author

Miki, Ikuya, primary, Kushida, Saeko, additional, Yamamoto, Yoshinobu, additional, Mimura, Takuya, additional, Takegawa, Naoki, additional, Tsumura, Hidetaka, additional, Sakamoto, Takeshi, additional, Tobimatsu, Kazutoshi, additional, Tsuda, Masahiro, additional, Nishisaki, Hogara, additional, and Inokuchi, Hideto, additional

Published
2013
Full Text
View/download PDF

35. Randomized phase II study of mixing steroid to reduce venous pain in patients with colorectal cancer receiving oxaliplatin through peripheral vein (APOLLO study).

Author

Hata, Taishi, primary, Toyokawa, Akihiro, additional, Kobayashi, Michiya, additional, Miyake, Masakazu, additional, Tsuda, Masahiro, additional, Tobimatsu, Kazutoshi, additional, Okamoto, Ken, additional, Tokunaga, Yukihiko, additional, Takase, Kozo, additional, Morita, Satoshi, additional, Sakamoto, Junichi, additional, and Mishima, Hideyuki, additional

Published
2013
Full Text
View/download PDF

39. Dok1 mediates high-fat diet–induced adipocyte hypertrophy and obesity through modulation of PPAR-γ phosphorylation

Author

Hosooka, Tetsuya, primary, Noguchi, Tetsuya, additional, Kotani, Ko, additional, Nakamura, Takehiro, additional, Sakaue, Hiroshi, additional, Inoue, Hiroshi, additional, Ogawa, Wataru, additional, Tobimatsu, Kazutoshi, additional, Takazawa, Kazuo, additional, Sakai, Mashito, additional, Matsuki, Yasushi, additional, Hiramatsu, Ryuji, additional, Yasuda, Tomoharu, additional, Lazar, Mitchell A, additional, Yamanashi, Yuji, additional, and Kasuga, Masato, additional

Published
2008
Full Text
View/download PDF

41. Impaired Consciousness Due to Hyperammonemia During S-1 Administration for Unresectable Pancreatic Cancer.

Author

Tokuyama N, Ikeda S, Ishida R, Futai R, Tobimatsu K, and Kodama Y

Abstract

A 71-year-old woman diagnosed with unresectable locally advanced pancreatic cancer was initially treated with gemcitabine and nab-paclitaxel as first-line therapy. The tumor exhibited no significant progression; however, after 12 cycles, the patient developed drug-induced interstitial pneumonia, leading to the discontinuation of gemcitabine and nab-paclitaxel therapy. Following recovery from pneumonia, S-1 therapy was initiated as second-line treatment. During S-1 treatment, she was hospitalized because of impaired consciousness and was subsequently diagnosed with hyperammonemia induced by S-1. Although rarely reported, S-1-induced hyperammonemia is potentially a significant adverse effect. Here, we herein report the case of a patient with pancreatic cancer.

Published
2024
Full Text
View/download PDF

42. Insulin-induced GLUT4 movements in C2C12 myoblasts: evidence against a role of conventional kinesin motor proteins.

Author

Takazawa K, Noguchi T, Hosooka T, Yoshioka T, Tobimatsu K, and Kasuga M

Subjects
14-3-3 Proteins metabolism, Animals, Cell Line, Cricetinae, Cyclic AMP metabolism, Cyclic AMP-Dependent Protein Kinases metabolism, Glucose Transporter Type 4 genetics, Humans, Kinesins genetics, Mice, Mutation genetics, Phosphorylation, Protein Binding, Protein Transport, Signal Transduction, Glucose Transporter Type 4 metabolism, Insulin pharmacology, Kinesins metabolism, Myoblasts drug effects, Myoblasts metabolism
Abstract

Insulin induces translocation of the glucose transporter GLUT4 from intracellular storage compartment to the plasma membrane via complex mechanisms that require intact cytoskeletal networks. In cultured adipocytes, conventional kinesin motor proteins have been proposed to mediate GLUT4 movements on microtubules. It remains, however, unclear whether kinesin motor system plays a similar regulatory role in myocytes. We addressed this issue using C2C12 myoblasts, which have now been shown to express both heavy and light chains of conventional kinesin. In these cells, overexpression of either wild-type kinesin light chain 2 (KLC2) or its phosphorylation-defective mutant did not significantly affect insulin-stimulated translocation of exofacial Myc-tagged GLUT4-green fluorescent protein to the cell surface and its subsequent externalization. Likewise, a dominant-negative mutant of KLC2 had no marked effect on GLUT4 movements in this cell type. These results suggest that conventional kinesin is dispensable for insulin-induced GLUT4 translocation in cultured myoblasts and may thus reveal a cell-type specific role of the microtubules-based cytoskeleton in glucose transport in response to insulin.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results